Meloxicam: intramuscular administration inrheumatology


Cite item

Full Text

About the authors

E S Tsvetkova

References

  1. Seibert K., Zhang Y. et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc. Natl. Acad. Sci. USA 1994; 91: 12013- 12014.
  2. Smith Y., Willis A. et al. Aspirin selectivity inhibits prostaglandin production in human platelets. Nature 1971; 231: 135-237.
  3. Насонов Е. Л., Цветкава Е. С. Селективные ингибиторы циклооксигеназы-2: новые перспективы лечения заболеваний человека. Тер. арх. 1998; 5: 8-14.
  4. Needleman P., Isokson P. The discovery and function of COX-J. Rheumatol. 1997; 24 (suppl. 49): 6-8.
  5. Vane J. Towards a better aspirin. Nature 1994; 367: 215-216.
  6. Насонов Е. Л. Нестероидные противовоспалительные препараты (перспективы применения в медицине). ML; 2000.
  7. Сасасе L. Elevated serum СРК after drug injections. N. Engl.J. Med. 1972; 287: 309-310.
  8. Combe В., Velicitet P., Garzon N. et al. Comparison of intramuscular and oral meloxicam in rheumatoid arthritis patients. Inflamm. Res. 2001; 50 (suppl. 1): S10-S16.
  9. Auvinet В., Ziler R., Appelboom T. et al. Comparison of the onset and intensity of action of intramuscular meloxicam and oral meloxicam in patients with acute sciatica. Clin. Ther. 1995; 17 (6): 78-90.
  10. Stei P., Kruss В., Wiegleb J. et al. Local tissue tolerability of meloxicam, a new NSAID: indications for parenteral, dermal and mucosal administration. Br. J. Rheumatol. 1996; 35 (1): 44-50.
  11. Narjes H., Turck D., Busch V. et el. Pharmacokinetics and tolerability of meloxicam after in administration. Br. J. Clin. Pharmacol. 1996; 41: 135-139.
  12. Colberg K., Netting M. et al. The efficacy and tolerability of an 8-day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. Curr. Med. Res. Opin. 1996; 13 (7): 363-377.
  13. Grozlan P., Bernhardt M., Velicitat P. et el. Tolerability of multiple administration of intramuscular meloxicam: a comparison with intramuscular piroxicam in patients with rheumatoid arthritis or osteoarthritis. Br. i. Rheumatol. 1996; 35 (I): 51 - 55.
  14. Bosch H., Sigmund R., Hettich M. Efficacy and tolerability of intramuscular and oral meloxicam in patients with acute lumbago: comparison with intramuscular and oral piroxicam. Curr. Med. Res. Opin. 1997; 14 (1): 29-38.
  15. Euller-Ziegler L., Velicitat P., Bluhmki E. et al. Meloxicam: a review of its pharmacokinetics, efficacy and tolerability following intramuscular administration. Inflamm. Res. 2001; 50 (suppl. 1): S5-S9.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2003 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies